Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 10,550,000 shares, a decline of 6.1% from the November 15th total of 11,230,000 shares. Based on an average daily volume of 788,200 shares, the short-interest ratio is presently 13.4 days. Currently, 19.5% of the company's shares are sold short.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently made changes to their positions in GPCR. Sandia Investment Management LP bought a new stake in Structure Therapeutics in the 2nd quarter valued at about $39,000. Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after acquiring an additional 719 shares in the last quarter. Quarry LP acquired a new position in shares of Structure Therapeutics during the second quarter worth approximately $79,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC acquired a new stake in Structure Therapeutics in the 3rd quarter valued at $202,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded up $0.48 on Tuesday, reaching $31.48. 483,460 shares of the company's stock were exchanged, compared to its average volume of 784,213. The company has a market capitalization of $1.80 billion, a P/E ratio of -41.58 and a beta of -3.41. Structure Therapeutics has a 52 week low of $26.61 and a 52 week high of $62.74. The firm's 50-day moving average is $36.13 and its two-hundred day moving average is $39.19.

Wall Street Analysts Forecast Growth

GPCR has been the topic of a number of recent research reports. HC Wainwright started coverage on shares of Structure Therapeutics in a report on Wednesday, December 4th. They set a "buy" rating and a $80.00 price target on the stock. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an "overweight" rating and a $118.00 target price on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics has an average rating of "Buy" and an average target price of $85.67.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.